OSE Immunotherapeutics
OSE.PADrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
OSE2101
Patients With Non-Small Cell Lung Cancer
OSE-127
Ulcerative Colitis
Part A: OSE-279 100mg
Solid Advanced Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OSE2101 | Phase 3 | Patients With Non-Small Cell Lung Cancer | - | - |
OSE-127 | Phase 2 | Ulcerative Colitis | - | - |
Part A: OSE-279 100mg | Phase 2 | Solid Advanced Tumor | - | - |
Frequently asked questions
What is in OSE Immunotherapeutics's drug pipeline?→
CatalystAlert tracks 3 drug candidates in OSE Immunotherapeutics's (OSE.PA) pipeline across Phase 3, Phase 2. Its lead program is OSE2101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is OSE Immunotherapeutics's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for OSE Immunotherapeutics (OSE.PA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track OSE.PA biotech catalysts?→
Add OSE.PA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow OSE Immunotherapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.